Ticker

Strata Critical Medical is rated a buy, driven by expanding market share, operational efficiencies, and a comprehensive suite of transplant logistics and clinical services. SRTA's asset-light-to-moderate model, strategic acquisitions, and focus on NRP technology position it to benefit from industry consolidation and secular tailwinds. Gross margin improvement is a key near-term catalyst, with management incentivized…

Network of experienced transplant surgeons in key markets will immediately become available to all Strata customers Adds significant scale to Transplant Clinical, Strata's fastest growing business line, with a similar, rapid growth trajectory $21.5 million acquisition completed at mid-single-digit multiple of Adjusted EBITDA, pre-synergy, consistent with Strata's capital deployment strategy NEW YORK, June 24, 2026…

Strata Critical Medical, Inc. (SRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that it has completed the acquisition of Louisville Perfusion Services, Inc. (“LPS”), a regional provider of perfusion and blood management services to cardiac surgery programs in Kentucky. “The acquisition of Louisville Perfusion Services fits perfectly with our existing customer base…

Directors bring a strong combination of technology, healthcare, national security, leadership experience, and financial and capital markets backgrounds AIAI Expected to Begin Trading on May 14, 2026   DALLAS, TX / ACCESS Newswire / May 12, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai2" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI to enhance portfolio performance,…